Thor Halfdanarson: More on Genomics of Gastrointestinal NECs
Thor Halfdanarson, Medical Oncologist at the Mayo Clinic, shared a post on X about a paper by T. Ozato et al. published in ESMO Gastrointestinal Oncology:
“More on genomics of NECs – nothing really new but nice lit addition nonetheless…
Repeat after me: Extrapulmonary NECs are not SCLC (and why do we assume SCLC chemo is the best…?).
APC, KRAS, BRAF, and FBXW mutations are very common in colorectal NECs
Should colorectal and pancreatic NECs be treated more like the adenocarcinoma arising in the same location? Trials like FOLFIRINEC will help address that question, right…?”
Title: Genomic heterogeneity and clinical implications in gastrointestinal neuroendocrine carcinoma: MYC and KRAS as predictive biomarkers
Authors: T. Ozato, Y. Kono, H. Yamamoto, A. Hirasawa, D. Ennishi, S. Tomida, S. Toyooka, M. Otsuka
You can read the Full Article on ESMO Gastrointestinal Oncology.
More posts featuring Thor Halfdanarson.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023